Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Reilly

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|December 2, 2016
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteersMichael Schmohl, Stephan Glund, Akiko Harada, et al.
Heart (British Cardiac Society)|November 11, 2015
Dabigatran etexilate and reduction in serum apolipoprotein BPhilip Joseph, Guillaume Pare, Lars Wallentin, et al.
Lancet (London, England)|June 20, 2015
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialStephan Glund, Joachim Stangier, Michael Schmohl, et al.
Digestive Diseases and Sciences|March 28, 2018
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or DabigatranJennifer M Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, et al.
Clinical Pharmacokinetics|June 19, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib StudyStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Journal of the American College of Cardiology|May 7, 2016
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy VolunteersStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2016
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial FibrillationKathryn F Flack, Jay Desai, Jennifer M Kolb, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Circulation|December 28, 2018
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal BleedingSake J Van der Wall, Renato D Lopes, James Aisenberg, et al.
Circulation|May 7, 2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”Jeff S Healey, John Eikelboom, Sean Yang, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|December 2, 2016
Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteersMichael Schmohl, Stephan Glund, Akiko Harada, et al.
Heart (British Cardiac Society)|November 11, 2015
Dabigatran etexilate and reduction in serum apolipoprotein BPhilip Joseph, Guillaume Pare, Lars Wallentin, et al.
Lancet (London, England)|June 20, 2015
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trialStephan Glund, Joachim Stangier, Michael Schmohl, et al.
Digestive Diseases and Sciences|March 28, 2018
Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or DabigatranJennifer M Kolb, Kathryn Friedman Flack, Prapti Chatterjee-Murphy, et al.
Clinical Pharmacokinetics|June 19, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib StudyStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Journal of the American College of Cardiology|May 7, 2016
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy VolunteersStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 22, 2016
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial FibrillationKathryn F Flack, Jay Desai, Jennifer M Kolb, et al.
American Heart Journal|May 15, 2018
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?Noel Chan, Philip T Sager, Jack Lawrence, et al.
Circulation|December 28, 2018
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal BleedingSake J Van der Wall, Renato D Lopes, James Aisenberg, et al.
Circulation|May 7, 2013
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”Jeff S Healey, John Eikelboom, Sean Yang, et al.
Pageof 5